Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

“…impairment but not risk) and thus fail to measure important aspects of the disease (e.g. OCS use) [51]. Additionally, the ACQ was initially developed to assess clinically important differences in asthma control at the individual level (e.g.…”

“…Ultimately, future ideations of consensus definitions for clinical remission in severe asthma could incorporate a different or more comprehensive PRO assessment of asthma control, such as the Asthma Impairment and Risk Questionnaire (AIRQ) or the Predominant Symptom and Impairment Assessment (PSIA) [51,53]. Furthermore, regardless of clinical improvements, patients with a long history of asthma may not score as ''normal'' on the ACQ because of the presence of chronic symptoms, side effects from long-term OCS use, or other comorbidities.…”

“…Likewise, as discussed earlier, although other PRO tools (e.g. AIRQ or PSIA) may ultimately provide additional, and possibly more accurate, insights into levels of symptom control among patients with severe asthma, only ACQ-6 absolute scores were available from the benralizumab pivotal trials, which is why they were used for this post hoc analysis [51,53]. Finally, despite our efforts to identify similar patient populations between all three studies, differences between the trial designs (e.g.…”

Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America

“…U.S. patients and HCPs tend to underestimate the consequences of asthma symptoms, 39 relying predominantly on SABA for rapid relief. 28,40 These findings suggest the need for ICS administration, either as regular maintenance treatment or intermittently, to address variability in airway inflammation in SABA monotherapyetreated patients and lend support to the GINA recommendation of not distinguishing intermittent from mild persistent asthma.…”

The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

“…This is supported by the findings in the current analysis that patients with physician-assessed mild asthma can have severe exacerbations, and even exacerbations among those with well controlled asthma symptoms in the previous 4 weeks. Consequently, it would be interesting to assess the recently developed Asthma Impairment and Risk Questionnaire [37], which includes both asthma symptom control and exacerbation risk together, in patients with mild asthma.…”